Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Income (2016 - 2025)

Lineage Cell Therapeutics' Non Operating Income history spans 16 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 308.49% year-over-year to $2.2 million; the TTM value through Dec 2025 reached -$8.6 million, down 926.1%, while the annual FY2025 figure was -$32.0 million, N/A changed from the prior year.
  • Non Operating Income reached $2.2 million in Q4 2025 per LCTX's latest filing, up from -$10.6 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $6.3 million in Q4 2021 to a low of -$10.6 million in Q2 2025.
  • Average Non Operating Income over 5 years is -$255277.8, with a median of -$49000.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: skyrocketed 336.41% in 2023, then plummeted 11359.57% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $6.3 million in 2021, then plummeted by 111.85% to -$742000.0 in 2022, then soared by 322.1% to $1.6 million in 2023, then plummeted by 162.86% to -$1.0 million in 2024, then surged by 308.49% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Non Operating Income are $2.2 million (Q4 2025), -$10.6 million (Q2 2025), and -$185000.0 (Q1 2025).